BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Cyclacel Pharmaceuticals, Inc. 

200 Connell Drive
Suite 1500
Berkeley Heights  New Jersey  07922  U.S.A.
Phone: 908-517-7330 Fax: 866-271-3466


SEARCH JOBS

View Clinical Trials from BioPharm Insight









 Company News
Cyclacel Pharmaceuticals, Inc. (CYCC) To Present At 9th Annual JMP Securities Healthcare Conference 6/18/2014 8:43:28 AM
Cyclacel Pharmaceuticals, Inc. (CYCC) Provides Update On Its Clinical Development Plan Of Sapacitabine For Myelodysplastic Syndromes (MDS) 6/2/2014 9:46:38 AM
Cyclacel Pharmaceuticals, Inc. (CYCC) To Webcast Institutional Investor And Analyst Presentation On Clinical Development Plan Of Sapacitabine For MDS 5/28/2014 9:19:43 AM
Cyclacel Pharmaceuticals, Inc. (CYCC) To Release 2014 First Quarter Financial Results 5/7/2014 9:04:43 AM
Cyclacel Pharmaceuticals, Inc. (CYCC) Release: New Japanese Patents Issued Covering Sapacitabine Pharmaceutical Formulations And Combination Treatments 5/5/2014 9:19:17 AM
Cyclacel Pharmaceuticals, Inc. (CYCC) Announces Closing Of $10 Million Underwritten Offering 4/10/2014 7:58:07 AM
Cyclacel Pharmaceuticals, Inc. (CYCC) Release: Independent Investigators Present Non-Clinical Data Providing Rationale For Sapacitabine Combination Treatment With Bcr-Abl Inhibitors In CML 4/10/2014 7:51:38 AM
Cyclacel Pharmaceuticals, Inc. (CYCC) Announces $10 Million Underwritten Offering 4/4/2014 7:46:49 AM
Cyclacel Pharmaceuticals, Inc. (CYCC) Announces Proposed Public Offering Of Common Stock 4/4/2014 7:45:57 AM
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Fourth Quarter And Full Year 2013 Financial Results 3/26/2014 9:22:48 AM
12345678910...